IDEAS home Printed from https://ideas.repec.org/a/bdz/joimer/v3y2024i4p1-6.html

Alpha-Glucosidase Inhibitors (AGIs): A New Class of Oral Medication for Treatment of Type 2 Diabetes Patients

Author

Listed:
  • Devajit Mohajan

    (Department of Civil Engineering, Chittagong University of Engineering & Technology, Chittagong, Bangladesh)

  • Haradhan Kumar Mohajan

    (Department of Mathematics, Premier University, Chittagong, Bangladesh)

Abstract

α-Glucosidase inhibitors (AGIs) are a new class of antidiabetic drug that inhibits the absorption of carbohydrates from the gut and is exclusively used for the treatment of T2D. This group lowers blood glucose in a dose-dependent fashion by modifying the intestinal absorption of carbohydrates and fat. For T2D patients, postprandial hyperglycaemia control is essential for the maintaining recommended HbA1c goals, and AGIs are used as monotherapy or in combination with other antidiabetic medications to achieve normal glucose level. Acarbose, Miglitole, 1-deoxynojirimycin, and Voglibose are four AGIs, and among these; Acarbose has been shown to decrease the risk of progressing to diabetes in subjects with impaired glucose tolerance. In this mini review an attempt has been taken to discuss the aspects of AGIs with their efficacy and safety when a T2D patient uses these.

Suggested Citation

  • Devajit Mohajan & Haradhan Kumar Mohajan, 2024. "Alpha-Glucosidase Inhibitors (AGIs): A New Class of Oral Medication for Treatment of Type 2 Diabetes Patients," Journal of Innovations in Medical Research, Paradigm Academic Press, vol. 3(4), pages 1-6, December.
    • Handle: RePEc:bdz:joimer:v:3:y:2024:i:4:p:1-6
    DOI: 10.56397/JIMR/2024.12.01
    as

    Download full text from publisher

    File URL: https://www.paradigmpress.org/jimr/article/view/1381/1215
    Download Restriction: no
    File URL: https://libkey.io/10.56397/JIMR/2024.12.01?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bdz:joimer:v:3:y:2024:i:4:p:1-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Editorial Office (email available below). General contact details of provider: https://www.paradigmpress.org/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.